Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer.
Johmura Y, Maeda I, Suzuki N, Wu W, Goda A, Morita M, Yamaguchi K, Yamamoto M, Nagasawa S, Kojima Y, Tsugawa K, Inoue N, Miyoshi Y, Osako T, Akiyama F, Maruyama R, Inoue JI, Furukawa Y, Ohta T, Nakanishi M.
Johmura Y, et al.
J Clin Invest. 2018 Dec 3;128(12):5603-5619. doi: 10.1172/JCI121679. Epub 2018 Nov 12.
J Clin Invest. 2018.
PMID: 30418174
Free PMC article.